LordsMed partnership with Hindustan Antibiotics To Distribute Rapid Antigen Kits

LordsMed: LordsMed, the healthcare division of Lord’s Mark Industries, has entered into a distribution partnership with Hindustan Antibiotics Limited (HAL), a public-sector drug manufacturer. The Healthcare company will manufacture rapid antigen test kits at its ICMR-approved GMP and ISO-certified facility at Vasai, near Mumbai, Maharashtra, and distribute those kits in government healthcare centres across India at an affordable rate 10 per cent less than the average market rates.

The Company said The broadening of the distribution network is part of LordsMed’s goal of facilitating early-stage healthcare intervention and generating Rs 75 crore in revenue in six months. LordsMed has recently received  Indian Council of Medical Research (ICMR) approval to manufacture rapid antigen test kits at its Vasai facility for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, typhoid, COVID, chikungunya, ovulation, and pregnancy.

LordsMed said it has developed a robust R&D team comprised of experienced microbiologists and doctors and has emerged as the only IVD kit manufacturing company in India, working to roll out saliva-based diagnostic solutions for a range of diseases. The company has successfully carried out trials of its saliva-based diagnostics kits for diabetes and liver diseases.

Commenting on the partnership with HAL, Sachidanand Upadhyay, Founder, Lord’s Mark Industries, said, The distribution partnership with HAL will help us reach out to all parts of the country cities including metros, Tier -1, 2 and 3 cities and rural areas with our affordable and advanced rapid antigen test kits. The collaboration is a part of our mission to build a robust early-stage healthcare intervention framework and boost the responsiveness of the healthcare ecosystem.

The company stated its future plans to set up a manufacturing unit in Gujarat by 2023 and another facility in Lucknow, Uttar Pradesh, by 2024 to further boost its manufacturing capabilities and serve the growing market demand. The company also has plans to expand its exports to all countries in Africa and Europe.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March